KRAS and adenocarcinoma: Increasing molecular evidence supports the composite lesions hypothesis: shared alterations, such as KRAS, NF1, and BRAF V600E mutations, have been reported in both adenocarcinoma and carcinoid components, suggesting a monoclonal origin in select cases [8,9].